Company introduction: Teclison is a clinical stage biotech company that develops new cancer combination therapy aiming to maximize anti-tumor immunity to cure cancer.  The combination strategy includes 3 steps, (1) a rapid and effective reduction of tumor burden in liver, in which tumor lesions are highly refractory to immune checkpoint inhibitors; (2) convert tumor into an in-situ cancer vaccine to boost anti-tumor immunity; (3) addition of various immune modulators to eradicate systemic tumor lesions and prevent occurrence.  Currently the program is in phase 2 clinical study.  Preliminary results are highly promising and attract collaboration from major pharmas.
Therapeutic Areas: Cancer, applicable to all solid tumors with liver metastasis.

Anticipated market for metastatic colorectal cancer: USD $4 billion
Anticipated market for hepatocellular carcinoma: USD $1.8 billion

Four core team members are experts in clinical drug development in discovery/clinical/statistics/drug safety/BD, previously in major pharmas and each with at least 8 years of industrial experiences